Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
AMD: early-phase trial registry
3 of 6 indexed AMD trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 3 currently recruiting · #2,866 of 28,707 conditions by registered trial count
AMD: 6 US clinical trials tracked, 3 recruiting.
AMD is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is National Eye Institute (NEI), running 2 of these trials.
Enrollment posture brief
Registry condition amd
OPEN 3 | RECR 50% | LATE 1 | EARLY 2 | RANK #2866 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Achalasia (50% recruiting · 8 trials)
AMD lists 3 open slots (50% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for AMD on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
AMD is recruiting above its size-band peers.
3 of 6 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates AMD research.
National Eye Institute (NEI) accounts for 2 of 6 trials (33.3%). 4 distinct sponsors appear on at least one study for this condition label.
-
Typical AMD enrolment sits around 630 participants.
Median target enrolment is 630 among the 6 trials that report a genuine target (sentinel values excluded). 1 of those (16.7%) plan for fewer than 100 participants.
-
AMD splits between interventional and observational designs.
3 interventional and 3 observational studies make up this index (50% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Cell Collection to Study Eye Diseases
National Eye Institute (NEI)
NCT01432847
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
AbbVie
NCT05407636
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
AbbVie
NCT04704921
A Real-World Study of Interventional Clinical Outcomes in Patients With Open Angle Glaucoma and Other Chronic Eye Diseases
Interstat
NCT07216677
Phase 2/3 Study of ALK-001 in Geographic Atrophy
Alkeus Pharmaceuticals
NCT03845582
Study of the Effects of Supplements on Eye Disease in Participants From the Age-Related Eye Disease Study
National Eye Institute (NEI)
NCT01915238
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on AMD records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on AMD trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this AMD page
6 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 AMD trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Eye Institute (NEI) sponsors the most AMD trials on record, review their full trial history before evaluating a specific study. See National Eye Institute (NEI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This AMD condition card totals 6 registered trials; most-linked intervention ALK-001 oral capsule; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.